The incidence of childhood cancer increased through the second half of the 20th century and continues to increase today.
Incredible progress has been made in treating childhood cancers but the pace of progress has now slowed and a substantial minority of patients are failed by therapy and do not survive.
In addition, the tremendous gains in survival have been achieved through the use of increasingly intensive treatment regimens, putting young patients at risk of adverse, treatment-related effects.
In 2017, we made grants of over £5.8 million for research into childhood cancer (2016: £4.1 million).
In 2018, we will spend more than £3.6 million on research into childhood cancer.
We primarily award grants to institutions such as universities, medical and scientific research centres, and hospitals. We also award some fellowships and individual further professional development training awards.
Only researchers based at institutions in the UK can usually apply for funding. We fund research overseas only if it is part of an agreed collaborative effort.
Part of the criteria for the award of a grant is that there is adequate infrastructure to support the proposed work.
Oursets out the key areas of research we have decided we need to focus on.
Grant applications are invited via our different funding streams such as our Brain Tumour Initiative, Fellowships etc. These applications are rigorously assessed by members of our Scientific Advisory Panel with the assistance of expert external reviewers from around the world.
Children with Cancer UK is a member of the Association of Medical Research Charities (AMRC). The AMRC sets minimum standards of good practice to which member charities must adhere in their grant-making, including policies on peer review.
We keep in touch with grant-holders during the period of their grant to monitor their progress and keep track of findings.
Under our terms and conditions of funding, all grant-holders must provide annual reports on the progress of their project and a final report at the end of the grant.
We endeavour to visit each project at least once during the course of the grant – to meet the research team, inspect the research facilities and check on the progress of the work.
We place great importance on the dissemination of results, so that those working in the field can learn from other people’s research.
We closely monitor the progress of the projects we fund and encourage scientists to publish the results of their work where possible.
We provide additional funding for researchers to travel to conferences and meetings to present their work and discuss their findings.
We also host conferences and scientific workshops to bring together those engaged in childhood cancer research. In February 2016, we held a specialist workshop on drug delivery in childhood brain tumours; in September 2016 we are hosting our fourth international conference Childhood Cancer 2016, where a number of our grant-holders will present results from their research.
Children with Cancer UK is a member of the Association of Medical Research Charities (AMRC). We support the principle of using animals in research when it is necessary to advance understanding of health and disease and to develop new treatments; we want to find improved treatments that will cure even the hardest-to-treat forms of childhood cancer, causing minimal side effects for the child. This research only takes place where there is no alternative available; projects are only funded by us after rigorous assessment that specifically addresses the proposed use of animals.
All AMRC member charities support this principle, as outlined in this statement:
All research carried out in the UK involving animals is tightly regulated by the Home Office.
We have never funded any research using human embryos.
We have funded some work involving human embryonic stem cells.
References to the use of ‘stem cells’ in our research generally refer to blood stem cells rather than embryonic stem cells.
Children affected by the brain tumour known as ACP can have a positive future, but in many cases ...Read more
On Wednesday 29th March 2017, we launched our ground-breaking Precision Medicine project at the House of Commons. We ...Read more